Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Benjamin P. Sablan, Dong Joon Kim, Nina G. Barzaga, Wan Cheng Chow, Mong Cho, Sang Hoon Ahn, Seong Gyu Hwang, Ji Hyun Lee, Hamid Namini, William L. Heyward

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

Original languageEnglish
Pages (from-to)2689-2696
Number of pages8
JournalVaccine
Volume30
Issue number16
DOIs
Publication statusPublished - 2012 Mar 30

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Sablan, B. P., Kim, D. J., Barzaga, N. G., Chow, W. C., Cho, M., Ahn, S. H., Hwang, S. G., Lee, J. H., Namini, H., & Heyward, W. L. (2012). Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine, 30(16), 2689-2696. https://doi.org/10.1016/j.vaccine.2012.02.001